General and administrative spend declined 4.9% to $7.8 million, reflecting lower commercial planning costs, partially offset by higher stock-based compensation expense. Celldex is currently conducting a phase IIb study on glembatumumab …
The brief backstory is that the biotech's stock was hammered after its experimental brain cancer vaccine, Rintega, failed to improve overall survival in a late stage trial last year. Since then, Celldex's triple negative breast cancer (TNBC) drug ...
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company …
CELLDEX THERAPEUTICS INC, $3.9292 ... FBR Capital Markets downgraded the stock to “market perform” from “outperform”, saying the suspension was likely influenced by the company’s upcoming borrowing base redetermination.
Shares in drug developer Celldex Therapeutics (NASDAQ:CLDX) tanked over 52% in pre-market deals after an independent panel recommended its trial of Rintega for brain cancer be stopped due to disappointing results. Celldex
Celldex expects that this cash plus anticipated proceeds from future sales of its common stock under the agreement with Cantor will be enough to fund working capital requirements and planned operations through 2018. However, the …
(Reuters) - Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim ... sales would reduce his price target on the company's stock to $7 from $24. Celldex, which is …